Jean Bennett
Direttore/Membro del Consiglio presso REGENXBIO INC.
Patrimonio netto: 48 341 $ in data 30/04/2024
Posizioni attive di Jean Bennett
Società | Posizione | Inizio | Fine |
---|---|---|---|
REGENXBIO INC. | Direttore/Membro del Consiglio | 01/03/2021 | - |
Independent Dir/Board Member | 01/03/2021 | - | |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Direttore/Membro del Consiglio | 01/02/2021 | - |
Fondatore | 01/02/2021 | - | |
Perelman School of Medicine | Corporate Officer/Principal | - | - |
Storia della carriera di Jean Bennett
Precedenti posizioni note di Jean Bennett
Società | Posizione | Inizio | Fine |
---|---|---|---|
Limelight Bio, Inc.
Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Fondatore | - | - |
SPARK THERAPEUTICS, INC. | Fondatore | - | - |
Gensight Biologics, Inc. | Fondatore | - | - |
Center For Advanced Retinal & Ocular Therapies | Direttore/Membro del Consiglio | - | - |
Formazione di Jean Bennett
University of California, Berkeley | Doctorate Degree |
Harvard University | Doctorate Degree |
Yale University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 11 |
Posizioni
Founder | 4 |
Director/Board Member | 3 |
Doctorate Degree | 2 |
Settori
Health Technology | 5 |
Consumer Services | 5 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
REGENXBIO INC. | Health Technology |
Aziende private | 5 |
---|---|
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Health Technology |
Center For Advanced Retinal & Ocular Therapies | |
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Gensight Biologics, Inc. | |
Limelight Bio, Inc.
Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
- Borsa valori
- Insiders
- Jean Bennett
- Esperienza